ID

24028

Descripción

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone; ODM derived from: https://clinicaltrials.gov/show/NCT00528879

Link

https://clinicaltrials.gov/show/NCT00528879

Palabras clave

  1. 23/7/17 23/7/17 -
  2. 23/7/17 23/7/17 -
Subido en

23 de julio de 2017

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Type 2 Diabetes NCT00528879

Eligibility Type 2 Diabetes NCT00528879

Criteria
Descripción

Criteria

males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic control
Descripción

ID.1

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0001779
UMLS CUI [1,2]
C0011860
participants who have been receiving metformin at a total daily dose ≥1500 mg per day for at least 8 weeks
Descripción

ID.2

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0025598
c-peptide ≥1.0 ng/ml
Descripción

ID.3

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0202100
body mass index ≤45.0 kg/m^2
Descripción

ID.4

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
serum creatinine level <1.50 mg/dl for men or <1.40 mg/dl for women.
Descripción

ID.5

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0600061
key exclusion criteria
Descripción

key exclusion criteria

aspartate aminotransferase and/or alanine aminotransferase level >3.0 times the upper limit of normal
Descripción

ID.7

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0004002
UMLS CUI [1,2]
C0001899
serum total bilirubin level >2 mg/dl
Descripción

ID.8

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1278039
creatinine kinase level >3 times upper limit of normal
Descripción

ID.9

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1657311
symptoms of severely uncontrolled diabetes
Descripción

ID.10

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0810250
serum creatinine level 1.50 mg/dl for men or 1.40 mg/dl for women
Descripción

ID.11

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0600061
currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases
Descripción

ID.12

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0443343
UMLS CUI [1,2]
C0012634

Similar models

Eligibility Type 2 Diabetes NCT00528879

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
ID.1
Item
males and females, 18 to 77 years old, with type 2 diabetes and inadequate glycemic control
boolean
C0001779 (UMLS CUI [1,1])
C0011860 (UMLS CUI [1,2])
ID.2
Item
participants who have been receiving metformin at a total daily dose ≥1500 mg per day for at least 8 weeks
boolean
C0025598 (UMLS CUI [1])
ID.3
Item
c-peptide ≥1.0 ng/ml
boolean
C0202100 (UMLS CUI [1])
ID.4
Item
body mass index ≤45.0 kg/m^2
boolean
C1305855 (UMLS CUI [1])
ID.5
Item
serum creatinine level <1.50 mg/dl for men or <1.40 mg/dl for women.
boolean
C0600061 (UMLS CUI [1])
Item Group
key exclusion criteria
ID.7
Item
aspartate aminotransferase and/or alanine aminotransferase level >3.0 times the upper limit of normal
boolean
C0004002 (UMLS CUI [1,1])
C0001899 (UMLS CUI [1,2])
ID.8
Item
serum total bilirubin level >2 mg/dl
boolean
C1278039 (UMLS CUI [1])
ID.9
Item
creatinine kinase level >3 times upper limit of normal
boolean
C1657311 (UMLS CUI [1])
ID.10
Item
symptoms of severely uncontrolled diabetes
boolean
C0810250 (UMLS CUI [1])
ID.11
Item
serum creatinine level 1.50 mg/dl for men or 1.40 mg/dl for women
boolean
C0600061 (UMLS CUI [1])
ID.12
Item
currently unstable or serious cardiovascular, renal, hepatic, hematologic, oncologic, endocrine, psychiatric, or rheumatic diseases
boolean
C0443343 (UMLS CUI [1,1])
C0012634 (UMLS CUI [1,2])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial